Mar. 1 at 7:54 PM
$VSTM
The attachment shows actual & analyst projected VSTM AK/FAK combo product sales by quarter post FDA approval compared to 3 M&A exits including recent
$AVDL exit (& NUVB). FWIW the VSTM comparison to NUVB in this manner is not appropriate.
VSTM combo sales appear more or less consistent with all 3 peers who exited for EVs of
$1.7 to
$2.1B (though obviously TAM is not considered nor pipelines). However,
$CTIC Vonjo had roughly the same TAM as LGSOC, a limited patent life & no other pipeline of substance where VSTM has 7375 that has shown promise.
This is not investment advice. VSTM's valuation has been heading consistently lower since VSTM implemented meaningful C-suite changes in mid-December 2025. VSTM's share price is off almost 50% from its December 2025 peak
However, if actual product sales are a barometer of value potential then investors should consider researching VSTM for themselves.
$XBI $IBB
